Search companies

Live

NEXALIS THERAPEUTICS LTD (ASX: NX1)

Health care · News and insights

Price unavailable

Latest NX1 announcements

Nexalis Issues Settlement Options To Linlithgow Family Office

2026-11-11 · Health care

NX1: $0.008 +0.00% · MC: $2M

Nexalis Therapeutics has issued 15 million unlisted options to Linlithgow Family Office as settlement for funding received under its former facility. The options replace 38.4 million older options, which were cancelled when the facility was terminated; the settlement leaves no repayment obligation to the lender.

Updated 2026-11-11 13:01
Share
SourcesNotification regarding unquoted securities - NX1
Comments

Nexalis Ends LFO Facility, Replaces 38 Million Options With 15 Million

2026-10-30 · Health care

NX1: $0.009 +0.00% · MC: $2M

Nexalis Therapeutics says its LFO funding facility has been terminated by mutual agreement, with no repayment due and the lender’s security released; 38 million existing options have lapsed and the company proposes issuing 15 million replacement options to settle funding received. September-quarter cash fell to approximately $371,000 from $790,000 at the previous quarter-end, while the company says it is working to arrange forward funding against its research tax incentive and is seeking other funding for clinical trials.

Updated 2026-10-30 09:11
Share
SourcesNotification of cessation of securities - NX1Sep26 Appendix 4C Cash Flow ReportSep26 Quarterly Activities ReportProposed issue of securities - NX1
Comments